Disposition of Dibekacin in patients undergoing haemodialysis. 1980

J A Campillo, and J M Lanao, and A Dominguez-Gil, and F Rubio, and A Martin

The pharmacokinetics of Dibekacin were studied in 10 patients with terminal renal impairment (creatinine clearance < 5 ml/min) undergoing haemodialysis sessions lasting 4 h. The dialyzers were either the Gambro Lundia Major 13.5 or the Ultra Flo II 1.4., and the patients were divided into two groups according to the dialyzer used. Blood flow varied between 250 and 280 ml/min and dialyzate flow between 450 and 600 ml/min. All patients received a single i. v. dose of Dibekacin 1.5 mg/kg at the beginning of the dialysis session. The concentration of the antibiotic at the input and the output of the dialyzer were determine microbiologically by a plate diffusion method using B. subtilis as the test organism. The intravenously administered antibiotic followed an open two-compartment kinetic model. The type of dialyzer used did not influence the dialysis of Dibekacin. Haemodialysis significantly increased the elimination rate of the antibiotic with respect to the interdialysis periods. The plasma half-life in the slow disposition phase fell from 30 h in the interdialysis period to 4.0 h during dialysis sessions. From the calculated pharmacokinetic parameters, a dosage regimen for this kind of patient is proposed.

UI MeSH Term Description Entries
D007612 Kanamycin Antibiotic complex produced by Streptomyces kanamyceticus from Japanese soil. Comprises 3 components: kanamycin A, the major component, and kanamycins B and C, the minor components. Kanamycin A,Kanamycin Sulfate,Kantrex
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003982 Dibekacin Analog of KANAMYCIN with antitubercular as well as broad-spectrum antimicrobial properties. Dideoxykanamycin B,3',4'-Dideoxykanamycin B,Dibekacin Sulfate,Dibekacin Sulphate,Dideoxykanamycine,Orbicin,3',4' Dideoxykanamycin B,B, 3',4'-Dideoxykanamycin,Sulfate, Dibekacin,Sulphate, Dibekacin
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial

Related Publications

J A Campillo, and J M Lanao, and A Dominguez-Gil, and F Rubio, and A Martin
November 1995, International journal of clinical pharmacology and therapeutics,
J A Campillo, and J M Lanao, and A Dominguez-Gil, and F Rubio, and A Martin
January 1983, European journal of clinical pharmacology,
J A Campillo, and J M Lanao, and A Dominguez-Gil, and F Rubio, and A Martin
January 1987, International journal of clinical pharmacology, therapy, and toxicology,
J A Campillo, and J M Lanao, and A Dominguez-Gil, and F Rubio, and A Martin
April 1985, Antimicrobial agents and chemotherapy,
J A Campillo, and J M Lanao, and A Dominguez-Gil, and F Rubio, and A Martin
June 1993, British journal of urology,
J A Campillo, and J M Lanao, and A Dominguez-Gil, and F Rubio, and A Martin
January 1989, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
J A Campillo, and J M Lanao, and A Dominguez-Gil, and F Rubio, and A Martin
March 1969, Lancet (London, England),
J A Campillo, and J M Lanao, and A Dominguez-Gil, and F Rubio, and A Martin
February 1969, Lancet (London, England),
J A Campillo, and J M Lanao, and A Dominguez-Gil, and F Rubio, and A Martin
February 1969, Lancet (London, England),
J A Campillo, and J M Lanao, and A Dominguez-Gil, and F Rubio, and A Martin
August 1969, Lancet (London, England),
Copied contents to your clipboard!